|
|
 |
|
Viewing report
|
|
|
|
Fragile X Syndrome - Pipeline Review, H2 2011
Global Markets Direct, Nov 2011, Pages: 51
Fragile X Syndrome - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Fragile X Syndrome - Pipeline Review, H2 2011', provides an overview of the Fragile X Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. 'Fragile X Syndrome - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Fragile X Syndrome.
- A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Fragile X Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords
Fragile X Syndrome Therapeutic Products under Development, Key Players in Fragile X Syndrome Therapeutics, Fragile X Syndrome Pipeline Overview, Fragile X Syndrome Pipeline, Fragile X Syndrome Pipeline Assessment
|
|
|
|
